Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
24 mai 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth...
Exagen Inc. Reports First Quarter 2021 Results
11 mai 2021 16h05 HE
|
Exagen Inc.
Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
04 mai 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity...
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
03 mai 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of...
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
27 avr. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after...
Global Antinuclear Antibody Testing Market Predicted to Garner a Revenue of $2,766.5 Million at a CAGR of 13.0% during the Forecast Period, 2020-2027 - Absolute Report [Pages- 247] by Research Dive
19 avr. 2021 09h25 HE
|
Research Dive
New York, USA, April 19, 2021 (GLOBE NEWSWIRE) -- Research Dive has recently added a report to its online repository, titled “Antinuclear Antibody Testing Market, by Product (Reagents & Assay...
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
29 mars 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
25 mars 2021 16h15 HE
|
Exagen Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten...
Exagen Inc. Announces Pricing of Public Offering of Common Stock
22 mars 2021 22h01 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of...
Exagen Inc. Announces Proposed Public Offering of Common Stock
22 mars 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and...